GSK to supply Canada with 10,000 doses of COVID vaccine

GSK has signed an agreement with the Government of Canada to supply 10,000 doses of Sotrovimab for injection, a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology.

The agreement will enable provincial and territorial healthcare systems to access sotrovimab starting in October 2021 to treat patients with mild to moderate COVID-19 symptoms who are at high risk for progressing to hospitalisation or death.

The agreement includes the option for the Government of Canada to purchase additional doses in 2022 based on emerging needs.

Health Canada granted authorisation for Sotrovimab for injection in July, under its Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the treatment of mild to moderate COVID-19, confirmed by direct SARS-COV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high risk for progressing to hospitalisation and/or death.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news